Alnylam Pharmaceuticals Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
72.31
Forward P/E Ratio
20.71
PEG Ratio
-0.16
47.29
Price-to-Sales (TTM)
8.96
35.71
8.06
Market Cap
40.54B
38.16B
Is it profitable?
Net Profit Margin (TTM)
12.55%
Gross Profit Margin
81.91%
Diluted EPS (TTM)
3.98
90.36%
4.29B
Is it growing?
96.40%
96.43%
Is it risky?
0.30
276.20
3.13
2.97B
Who owns it?
102.05%
0.18%
5.39%
133.44M
132.94M
Does it pay?
0.00%
0.00%
--
--
How much cash?
3.01B
714.90M
204.71M
22.54
- Price
- 303.05
- Percent Change
- -0.59 (0.19%)
- Previous Close
- 303.64
- Open
- 306.77
- Low
- 300.49
- High
- 306.77
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$303.05
From 52W Low
+7.05%
From 52W High
-38.85%
Today
-0.19%
1Y Change
-1.61%
6M
$458.12
3M
$320.51
1M
$301.11
Today
$303.05
From 52W Low
+7.05%
From 52W High
-38.85%
Today
-0.19%
1Y Change
-1.61%
6M
$458.12
3M
$320.51
1M
$301.11
Today
$303.05
Cheap
within its 1-year price range
$303.05
Multi-Timeframe Analysis (MTA)
Reversal Signal
Short-term price is rising while the longer trend remains negative. In technical analysis this is called a reversal signal. The trend may be turning, but confirmation across more periods is needed before it becomes an uptrend. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+0.6%
3M
-5.4%
6M
-33.8%
1Y
-1.6%
Rate of Change (ROC)
Decelerating
Price has reversed, now rising vs its usual downtrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Alnylam Pharmaceuticals Inc.
- Founded
- 2002
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Fiscal Year End
- Dec 31, 2024
- Address
675 West Kendall Street
Cambridge
MA
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.alnylam.com
Indicators
Operating Cash Flow
714.90M
Net Income
537.99M
Real Earnings
1.33
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |
Indicators
Operating Cash Flow
714.90M
Net Income
537.99M
Real Earnings
1.33
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
72.31
Forward P/E Ratio
20.71
PEG Ratio
-0.16
47.29
Price-to-Sales (TTM)
8.96
35.71
8.06
Market Cap
40.54B
38.16B
Is it profitable?
Net Profit Margin (TTM)
12.55%
Gross Profit Margin
81.91%
Diluted EPS (TTM)
3.98
90.36%
4.29B
Is it growing?
96.40%
96.43%
Is it risky?
0.30
276.20
3.13
2.97B
Who owns it?
102.05%
0.18%
5.39%
133.44M
132.94M
Does it pay?
0.00%
0.00%
--
--
How much cash?
3.01B
714.90M
204.71M
22.54
- Price
- 303.05
- Percent Change
- -0.59 (0.19%)
- Previous Close
- 303.64
- Open
- 306.77
- Low
- 300.49
- High
- 306.77
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$303.05
From 52W Low
+7.05%
From 52W High
-38.85%
Today
-0.19%
1Y Change
-1.61%
6M
$458.12
3M
$320.51
1M
$301.11
Today
$303.05
From 52W Low
+7.05%
From 52W High
-38.85%
Today
-0.19%
1Y Change
-1.61%
6M
$458.12
3M
$320.51
1M
$301.11
Today
$303.05
Cheap
within its 1-year price range
$303.05
Multi-Timeframe Analysis (MTA)
Reversal Signal
Short-term price is rising while the longer trend remains negative. In technical analysis this is called a reversal signal. The trend may be turning, but confirmation across more periods is needed before it becomes an uptrend. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+0.6%
3M
-5.4%
6M
-33.8%
1Y
-1.6%
Rate of Change (ROC)
Decelerating
Price has reversed, now rising vs its usual downtrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Alnylam Pharmaceuticals Inc.
- Founded
- 2002
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Fiscal Year End
- Dec 31, 2024
- Address
675 West Kendall Street
Cambridge
MA
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.alnylam.com
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |